Cargando…
Compassionate Use of the ROCK Inhibitor Fasudil in Three Patients With Amyotrophic Lateral Sclerosis
The Rho kinase (ROCK) inhibitor Fasudil is a promising drug for a disease-modifying therapy of amyotrophic lateral sclerosis (ALS). In preclinical models, Fasudil was shown to increase motor neuron survival, inhibit axonal degeneration, enhance axonal regeneration and modulate microglial function in...
Autores principales: | Koch, Jan C., Kuttler, Josua, Maass, Fabian, Lengenfeld, Teresa, Zielke, Eirini, Bähr, Mathias, Lingor, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083210/ https://www.ncbi.nlm.nih.gov/pubmed/32231638 http://dx.doi.org/10.3389/fneur.2020.00173 |
Ejemplares similares
-
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
por: Lingor, Paul, et al.
Publicado: (2019) -
Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset
por: Günther, René, et al.
Publicado: (2017) -
Destination Amyotrophic Lateral Sclerosis
por: Keon, Matt, et al.
Publicado: (2021) -
Biomarkers of Metabolism in Amyotrophic Lateral Sclerosis
por: Kirk, Siobhan E., et al.
Publicado: (2019) -
Functional Biomarkers for Amyotrophic Lateral Sclerosis
por: Huynh, William, et al.
Publicado: (2019)